BR9607964A - Processo de preparação de um medicamento para tratar doença inflamatória do intestino - Google Patents

Processo de preparação de um medicamento para tratar doença inflamatória do intestino

Info

Publication number
BR9607964A
BR9607964A BR9607964-9A BR9607964A BR9607964A BR 9607964 A BR9607964 A BR 9607964A BR 9607964 A BR9607964 A BR 9607964A BR 9607964 A BR9607964 A BR 9607964A
Authority
BR
Brazil
Prior art keywords
preparing
drug
inflammatory bowel
bowel disease
treat inflammatory
Prior art date
Application number
BR9607964-9A
Other languages
English (en)
Inventor
William J Sandborn
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of BR9607964A publication Critical patent/BR9607964A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSO DE PREPARAçãO DE UM MEDICAMENTO, FORMA DE DOSAGEM UNITáRIA, MICROPARTìCULAS ENTERCIAMENTE REVESTIDAS, E, COMPOSIçãO FARMACêUTICA". é fornecido um processo para tratar doença inflamatória de bexiga por administração topicamente ao cólon de uma quantidade de azatioprina ou de um sal farmaceuticamente aceitável da mesma, de preferência por meio de formulações adaptadas para administração oral ou retal de liberação retardada.
BR9607964-9A 1995-03-30 1996-03-12 Processo de preparação de um medicamento para tratar doença inflamatória do intestino BR9607964A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/413,505 US5691343A (en) 1995-03-30 1995-03-30 Use of topical azathioprine to treat inflammatory bowel disorders
PCT/US1996/003383 WO1996030021A1 (en) 1995-03-30 1996-03-12 Azathioprine compositions for colonic administration

Publications (1)

Publication Number Publication Date
BR9607964A true BR9607964A (pt) 1999-11-30

Family

ID=23637470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607964-9A BR9607964A (pt) 1995-03-30 1996-03-12 Processo de preparação de um medicamento para tratar doença inflamatória do intestino

Country Status (18)

Country Link
US (2) US5691343A (pt)
EP (1) EP0817634A1 (pt)
JP (1) JPH11502842A (pt)
KR (1) KR19980703423A (pt)
AP (1) AP727A (pt)
AU (1) AU707168B2 (pt)
BR (1) BR9607964A (pt)
CA (1) CA2216728A1 (pt)
CZ (1) CZ290428B6 (pt)
EA (1) EA199700282A1 (pt)
HU (1) HUP9801241A3 (pt)
IS (1) IS4561A (pt)
NO (2) NO311491B1 (pt)
NZ (1) NZ306062A (pt)
OA (1) OA10517A (pt)
PL (1) PL322526A1 (pt)
TR (1) TR199701079T1 (pt)
WO (1) WO1996030021A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2304948C (en) * 1997-09-26 2009-12-29 Medeva Europe Limited Pharmaceutical composition for the treatment of inflammatory bowel disease
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US7323471B1 (en) 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
US6946258B2 (en) 2002-03-04 2005-09-20 Biologix Diagnostics, Llc Rapid, immunochemical process for measuring thiopurine methyltransferase
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7067460B2 (en) 2002-11-14 2006-06-27 Baker Hughes Incorporated Organofunctional compounds for shale stabilization of the aqueous dispersed phase of non-aqueous based invert emulsion drilling system fluids
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
JP2007530692A (ja) * 2004-04-01 2007-11-01 テバ ファーマシューティカル インダストリーズ リミティド ６−メルカプトプリンの改良された製剤
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
US7919251B2 (en) * 2007-10-12 2011-04-05 Guy's And St. Thomas' Nhs Foundation Trust Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy
US20090263482A1 (en) * 2008-04-18 2009-10-22 Vered Rosenberger Treatment of inflammatory bowel disease with 6-mercaptopurine
US11077112B2 (en) 2015-09-29 2021-08-03 ProdrugXtend Pty Ltd Formulation and treatment methods
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056785A (en) * 1960-03-21 1962-10-02 Burroughs Weilcome & Co U S A Purine derivatives
US4350690A (en) * 1980-10-27 1982-09-21 Cressington Investments Ltd. Steroid composition
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
JPS6272618A (ja) * 1985-09-27 1987-04-03 Kanji Takada アザチオプリン製剤
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling

Also Published As

Publication number Publication date
NO20012930L (no) 1997-09-25
CZ290428B6 (cs) 2002-07-17
CZ309297A3 (cs) 1998-03-18
JPH11502842A (ja) 1999-03-09
HUP9801241A3 (en) 2000-06-28
HUP9801241A2 (hu) 1998-09-28
KR19980703423A (ko) 1998-11-05
NZ306062A (en) 1998-10-28
NO20012930D0 (no) 2001-06-13
CA2216728A1 (en) 1996-10-03
AP9701098A0 (en) 1997-10-31
NO311491B1 (no) 2001-12-03
TR199701079T1 (xx) 1998-01-21
AU5421896A (en) 1996-10-16
US5905081A (en) 1999-05-18
EA199700282A1 (ru) 1998-04-30
AU707168B2 (en) 1999-07-01
IS4561A (is) 1997-09-18
NO974440L (no) 1997-09-25
MX9707391A (es) 1997-11-29
OA10517A (en) 2002-04-24
EP0817634A1 (en) 1998-01-14
PL322526A1 (en) 1998-02-02
US5691343A (en) 1997-11-25
WO1996030021A1 (en) 1996-10-03
NO974440D0 (no) 1997-09-25
AP727A (en) 1999-01-29

Similar Documents

Publication Publication Date Title
BR9607964A (pt) Processo de preparação de um medicamento para tratar doença inflamatória do intestino
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
BR122012014331B8 (pt) formulações farmacêuticas
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
CA2380673A1 (en) Compositions comprising modafinil for treatment of attention deficit hyperactivity disorder
WO2000050027A1 (en) Gabapentin derivative for preventing and treating visceral pain
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
JP2002502871A5 (pt)
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
KR930009605A (ko) 소염 또는 진통제
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
KR970061244A (ko) 치매 치료용 약학 조성물
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR9704114A (pt) Processo de tratamento de doenças vasculares progressivas crÈnicas
BR9809396A (pt) Método de tratamento de doenças de cicatrização vascular progressivas
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
WO1997044045A1 (en) Malatonin in combination with analgesics
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
US4575506A (en) Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
CN112972448B (zh) 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal